Philippe van Wilder1, Irina Odnoletkova1, Mehdi Mouline1, Esther de Vries2,3. 1. Research Centre in Health Economics, School of Public Health, Université Libre de Bruxelles, Brussels, Belgium. 2. Dept Tranzo, Tilburg School of Social and Behavioral Sciences, Tilburg University, Tilburg, The Netherlands. 3. Laboratory of Medical Microbiology and Immunology, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands.
Abstract
BACKGROUND: Common variable immunodeficiency disorders (CVID), the most common form of primary antibody deficiency, are rare conditions associated with considerable morbidity and mortality. The clinical benefit of immunoglobulin replacement therapy (IgGRT) is substantial: timely treatment with appropriate doses significantly reduces mortality and the incidence of CVID-complications such as major infections and bronchiectasis. Unfortunately, CVID-patients still face a median diagnostic delay of 4 years. Their disease burden, expressed in annual loss of disability-adjusted life years, is 3-fold higher than in the general population. Hurdles to treatment access and reimbursement by healthcare payers may exist because the value of IgGRT is poorly documented. This paper aims to demonstrate cost-effectiveness and cost-utility (on life expectancy and quality) of IgGRT in CVID. METHODS AND FINDINGS: With input from a literature search, we built a health-economic model for cost-effectiveness and cost-utility assessment of IgGRT in CVID. We compared a mean literature-based dose (≥450mg/kg/4wks) to a zero-or-low dose (0 to ≤100 mg/kg/4wks) in a simulated cohort of adult patients from time of diagnosis until death; we also estimated the economic impact of diagnostic delay in this simulated cohort. Compared to no or minimal treatment, IgGRT showed an incremental benefit of 17 life-years (LYs) and 11 quality-adjusted life-years (QALYs), resulting in an incremental cost-effectiveness ratio (ICER) of €29,296/LY and €46,717/QALY. These results were robust in a sensitivity analysis. Reducing diagnostic delay by 4 years provided an incremental benefit of six LYs and four QALYs compared to simulated patients with delayed IgGRT initiation, resulting in an ICER of €30,374/LY and €47,495/QALY. CONCLUSIONS: The health-economic model suggests that early initiation of IgGRT compared to no or delayed IgGRT is highly cost-effective. CVID-patients' access to IgGRT should be facilitated, not only because of proven clinical efficacy, but also due to the now demonstrated cost-effectiveness.
BACKGROUND: Common variable immunodeficiency disorders (CVID), the most common form of primary antibody deficiency, are rare conditions associated with considerable morbidity and mortality. The clinical benefit of immunoglobulin replacement therapy (IgGRT) is substantial: timely treatment with appropriate doses significantly reduces mortality and the incidence of CVID-complications such as major infections and bronchiectasis. Unfortunately, CVID-patients still face a median diagnostic delay of 4 years. Their disease burden, expressed in annual loss of disability-adjusted life years, is 3-fold higher than in the general population. Hurdles to treatment access and reimbursement by healthcare payers may exist because the value of IgGRT is poorly documented. This paper aims to demonstrate cost-effectiveness and cost-utility (on life expectancy and quality) of IgGRT in CVID. METHODS AND FINDINGS: With input from a literature search, we built a health-economic model for cost-effectiveness and cost-utility assessment of IgGRT in CVID. We compared a mean literature-based dose (≥450mg/kg/4wks) to a zero-or-low dose (0 to ≤100 mg/kg/4wks) in a simulated cohort of adult patients from time of diagnosis until death; we also estimated the economic impact of diagnostic delay in this simulated cohort. Compared to no or minimal treatment, IgGRT showed an incremental benefit of 17 life-years (LYs) and 11 quality-adjusted life-years (QALYs), resulting in an incremental cost-effectiveness ratio (ICER) of €29,296/LY and €46,717/QALY. These results were robust in a sensitivity analysis. Reducing diagnostic delay by 4 years provided an incremental benefit of six LYs and four QALYs compared to simulated patients with delayed IgGRT initiation, resulting in an ICER of €30,374/LY and €47,495/QALY. CONCLUSIONS: The health-economic model suggests that early initiation of IgGRT compared to no or delayed IgGRT is highly cost-effective. CVID-patients' access to IgGRT should be facilitated, not only because of proven clinical efficacy, but also due to the now demonstrated cost-effectiveness.
Authors: Jordan S Orange; Joseph T Glessner; Elena Resnick; Kathleen E Sullivan; Mary Lucas; Berne Ferry; Cecilia E Kim; Cuiping Hou; Fengxiang Wang; Rosetta Chiavacci; Subra Kugathasan; John W Sleasman; Robert Baldassano; Elena E Perez; Helen Chapel; Charlotte Cunningham-Rundles; Hakon Hakonarson Journal: J Allergy Clin Immunol Date: 2011-04-17 Impact factor: 10.793
Authors: Elliot Marseille; Bruce Larson; Dhruv S Kazi; James G Kahn; Sydney Rosen Journal: Bull World Health Organ Date: 2014-12-15 Impact factor: 9.408
Authors: Irina Odnoletkova; Gerhard Kindle; Isabella Quinti; Bodo Grimbacher; Viviane Knerr; Benjamin Gathmann; Stephan Ehl; Nizar Mahlaoui; Philippe Van Wilder; Kris Bogaerts; Esther de Vries Journal: Orphanet J Rare Dis Date: 2018-11-12 Impact factor: 4.123
Authors: Sampsa Pikkarainen; Timi Martelius; Ari Ristimäki; Sanna Siitonen; Mikko R J Seppänen; Martti Färkkilä Journal: Am J Gastroenterol Date: 2019-04 Impact factor: 10.864